NO20060257L - Fremgangsmate for diagnostikk og prognostisering av Alzhcimers sykdom - Google Patents

Fremgangsmate for diagnostikk og prognostisering av Alzhcimers sykdom

Info

Publication number
NO20060257L
NO20060257L NO20060257A NO20060257A NO20060257L NO 20060257 L NO20060257 L NO 20060257L NO 20060257 A NO20060257 A NO 20060257A NO 20060257 A NO20060257 A NO 20060257A NO 20060257 L NO20060257 L NO 20060257L
Authority
NO
Norway
Prior art keywords
disease
alzheimer
prognosis
diagnosis
procedures
Prior art date
Application number
NO20060257A
Other languages
English (en)
Inventor
Laurent Pradier
Sylvain Ricard
Jean-Francois Deleuze
Sandrine Mace
Jesus Benavides
Emanuelle Cousin
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20060257L publication Critical patent/NO20060257L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Det beskrives metoder for diagnose eller prognose av Alzheimers sykdom hos et individ. Denne fremgangsmåte har minst ett trinn for detektering av nærværet eller fiiaværet av minoritærallelen av polymorfismen rs908832 av genet ABCA2. Nærværet av denne minoritetsallel av polymorfismen rs908832 av genet ABCA2 indikerer at individet kan få Alzheimers sykdom eller har en øket risiko for å utvikle Alzheimers sykdom.
NO20060257A 2003-06-20 2006-01-18 Fremgangsmate for diagnostikk og prognostisering av Alzhcimers sykdom NO20060257L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0307501A FR2856409B1 (fr) 2003-06-20 2003-06-20 Methodes de detection de la maladie d'alzheimer
PCT/FR2004/001509 WO2004113568A2 (fr) 2003-06-20 2004-06-17 Méthodes de détection de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
NO20060257L true NO20060257L (no) 2006-01-18

Family

ID=33484616

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060257A NO20060257L (no) 2003-06-20 2006-01-18 Fremgangsmate for diagnostikk og prognostisering av Alzhcimers sykdom

Country Status (24)

Country Link
EP (1) EP1639139B1 (no)
JP (1) JP4691491B2 (no)
KR (1) KR101170651B1 (no)
CN (1) CN1809645B (no)
AR (1) AR044492A1 (no)
AT (1) ATE518005T1 (no)
AU (1) AU2004249919B2 (no)
BR (1) BRPI0411658A (no)
CA (1) CA2529633C (no)
CY (1) CY1111970T1 (no)
DK (1) DK1639139T3 (no)
ES (1) ES2370491T3 (no)
FR (1) FR2856409B1 (no)
HR (1) HRP20110778T1 (no)
IL (1) IL172690A0 (no)
MX (1) MXPA05012800A (no)
NO (1) NO20060257L (no)
PL (1) PL1639139T3 (no)
PT (1) PT1639139E (no)
RU (2) RU2380423C2 (no)
SI (1) SI1639139T1 (no)
TW (1) TWI352738B (no)
WO (1) WO2004113568A2 (no)
ZA (1) ZA200509945B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2315559C1 (ru) * 2006-10-13 2008-01-27 Иван Васильевич Максимович Способ комплексной лучевой диагностики доклинических и клинических стадий болезни альцгеймера
CN103013989A (zh) * 2011-09-23 2013-04-03 深圳北京大学香港科技大学医学中心 与老年痴呆症发病相关的细胞周期依赖性激酶5的单核苷酸多态性位点
GB201212084D0 (en) * 2012-07-06 2012-08-22 Randox Lab Ltd Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment
CN102768189B (zh) * 2012-07-30 2014-11-19 黄石 一种药物筛选方法
CN104313144B (zh) * 2014-10-16 2017-02-01 卫生部北京医院 一种检测阿尔茨海默病易感性的试剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853995A (en) * 1997-01-07 1998-12-29 Research Development Foundation Large scale genotyping of diseases and a diagnostic test for spinocerebellar ataxia type 6
JP2003509017A (ja) * 1999-08-20 2003-03-11 アクティブ パス ファーマシューティカルズ， インコーポレイテッド ヒトａｂｃ２輸送体およびその使用
AU2001276995C1 (en) * 2000-07-20 2006-10-26 Cephalon, Inc. Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring
JP2004147502A (ja) * 2000-07-26 2004-05-27 Banyu Pharmaceut Co Ltd ヒト及びラットａｂｃａ２遺伝子
WO2002064781A2 (en) * 2001-02-09 2002-08-22 Active Pass Pharmaceuticals, Inc. Regulation of amyloid precursor protein expression by modification of abc transporter expression or activity
JP2004538450A (ja) * 2001-06-08 2004-12-24 ゼノン ジェネティクス，インコーポレイテッド 神経系統障害及び生殖器官障害の治療法

Also Published As

Publication number Publication date
AU2004249919B2 (en) 2009-08-13
RU2009104533A (ru) 2010-08-20
ES2370491T3 (es) 2011-12-16
CA2529633C (fr) 2014-08-05
TWI352738B (en) 2011-11-21
RU2380423C2 (ru) 2010-01-27
RU2006101561A (ru) 2006-06-10
CN1809645A (zh) 2006-07-26
HK1090392A1 (en) 2006-12-22
CA2529633A1 (fr) 2004-12-29
AR044492A1 (es) 2005-09-14
IL172690A0 (en) 2006-04-10
PL1639139T3 (pl) 2011-12-30
TW200517502A (en) 2005-06-01
AU2004249919A1 (en) 2004-12-29
PT1639139E (pt) 2011-10-24
HRP20110778T1 (hr) 2011-11-30
EP1639139A2 (fr) 2006-03-29
CY1111970T1 (el) 2015-11-04
DK1639139T3 (da) 2011-11-21
WO2004113568A2 (fr) 2004-12-29
FR2856409A1 (fr) 2004-12-24
FR2856409B1 (fr) 2007-08-31
KR101170651B1 (ko) 2012-08-03
BRPI0411658A (pt) 2006-08-08
JP2007515151A (ja) 2007-06-14
SI1639139T1 (sl) 2011-11-30
ZA200509945B (en) 2007-03-28
RU2483108C2 (ru) 2013-05-27
EP1639139B1 (fr) 2011-07-27
MXPA05012800A (es) 2006-05-17
CN1809645B (zh) 2013-11-20
JP4691491B2 (ja) 2011-06-01
ATE518005T1 (de) 2011-08-15
WO2004113568A3 (fr) 2005-05-06
KR20060029232A (ko) 2006-04-05

Similar Documents

Publication Publication Date Title
Guo et al. Three-stage quality control strategies for DNA re-sequencing data
Cuyvers et al. Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond
Drew et al. Improved inherited peripheral neuropathy genetic diagnosis by whole‐exome sequencing
Guo et al. Very low-level heteroplasmy mtDNA variations are inherited in humans
Sassi et al. Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease
Donner et al. Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer
Wong et al. The genetic diversity of cystinuria in a UK population of patients
Maia et al. Identification of two novel HOXB13 germline mutations in Portuguese prostate cancer patients
Liu et al. Genome-wide linkage, exome sequencing and functional analyses identify ABCB6 as the pathogenic gene of dyschromatosis universalis hereditaria
Chung et al. A novel mutation of TMPRSS3 related to milder auditory phenotype in Korean postlingual deafness: a possible future implication for a personalized auditory rehabilitation
Meyer et al. Association between brown eye colour in rs12913832: GG individuals and SNPs in TYR, TYRP1, and SLC24A4
Krawitz et al. Screening for single nucleotide variants, small indels and exon deletions with a next‐generation sequencing based gene panel approach for U sher syndrome
Kim et al. Genetic analysis of genes related to tight junction function in the Korean population with non-syndromic hearing loss
WO2012031207A3 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
Nguyen-Dumont et al. Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?
WO2020231081A1 (ko) Top3b 유전자 변이 기반 치매 진단방법
Anderson et al. The challenges of chromosome Y analysis and the implications for chronic kidney disease
WO2017218798A1 (en) Systems and methods for diagnosing familial hypercholesterolemia
Jelsig et al. Whole genome sequencing and disease pattern in patients with juvenile polyposis syndrome: a nationwide study
WO2004058051A3 (en) Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
Cesca et al. A novel mutation of the EYA4 gene associated with post-lingual hearing loss in a proband is co-segregating with a novel PAX3 mutation in two congenitally deaf family members
Markocsy et al. Complex analysis of the national Hereditary angioedema cohort in Slovakia–Identification of 12 novel variants in SERPING1 gene
Wolf et al. Efficiency of the revised Bethesda guidelines (2003) for the detection of mutations in mismatch repair genes in Austrian HNPCC patients
WO2007086980A3 (en) Methods of determining the risk of developing coronary artery disease
CY1111970T1 (el) Μεθοδοι για την ανιχνευση της νοσου αλτσχαϊμερ

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application